Please try another search
For the three months ended 31 March 2022, Korea Arlico Pharm Co Ltd revenues increased 37% to W42.93B. Net income increased 34% to W2.89B. Revenues reflect Special Medication segment increase of 34% to W41.78B, Other segment increase from W46M to W1.13B. Net income was partially offset by Marketing Commission increase of 36% to W20.19B (expense), Research & Development Expense increase of 97% to W2.28B (expense).
Period Ending: | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Total Revenue | 50059.2 | 47551.31 | 44093.6 | 42383.82 |
Gross Profit | 31048.74 | 29014.88 | 26517.08 | 28100.79 |
Operating Income | 5310.27 | 3042.59 | 432.14 | 3473.72 |
Net Income | 4680.91 | 2556.07 | 309.33 | 2396.29 |
Period Ending: | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Total Assets | 164652.17 | 162506.01 | 153536.15 | 147712.54 |
Total Liabilities | 70746.2 | 73318.46 | 64990.04 | 59883.51 |
Total Equity | 93905.97 | 89187.56 | 88546.12 | 87829.03 |
Period Ending: | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 2934.47 | 3414.51 | 1464.13 | -855.84 |
Cash From Investing Activities | -2550.07 | -5149.64 | -5743.71 | -3356.91 |
Cash From Financing Activities | 25.42 | 3376.32 | -245.55 | 5716.02 |
Net Change in Cash | 417.61 | 1680.23 | -4831.16 | 1636.02 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review